Pleiotropic roles of Notch signaling in normal, malignant, and developmental hematopoiesis in the human

EMBO Reports

Volumn 15, Issue 11, 2014, Pages 1128-1138

  Kushwah, Rahul ^a   Guezguez, Borhane ^a   Lee, Jung Bok ^a   Hopkins, Claudia I ^a   Bhatia, Mickie ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

Hematopoiesis; Human pluripotent stem cells; Leukemia; Notch

Indexed keywords

ALPHA SECRETASE INHIBITOR; ANTILEUKEMIC AGENT; BORTEZOMIB; GAMMA SECRETASE INHIBITOR; GLUCOCORTICOID; JAGGED1; NOTCH RECEPTOR; NOTCH RECEPTOR ANTIBODY; NOTCH1 RECEPTOR; NOTCH2 RECEPTOR; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; B CELL LEUKEMIA; BONE MARROW; CHRONIC MYELOMONOCYTIC LEUKEMIA; HEMATOLOGIC MALIGNANCY; HEMATOPOIESIS; HEMATOPOIETIC SYSTEM; HUMAN; MICROENVIRONMENT; NONHUMAN; PLEIOTROPY; PLURIPOTENT STEM CELL; RENDU OSLER WEBER DISEASE; REVIEW; T CELL LYMPHOMA; GENETICS; LEUKEMIA; METABOLISM; SIGNAL TRANSDUCTION;

GENETIC PLEIOTROPY; HEMATOPOIESIS; HUMANS; LEUKEMIA; RECEPTORS, NOTCH; SIGNAL TRANSDUCTION;

EID: 84910153374     PISSN: 1469221X     EISSN: 14693178     Source Type: Journal    
DOI: 10.15252/embr.201438842     Document Type: Review

References (104)

1. Demerec M, Fano U (1941) Mechanism of the origin of x-ray induced notch deficiencies in Drosophila melanogaster. Proc Natl Acad Sci USA 27: 24-31
2. Ellisen LW, Bird J, West DC, Soreng AL, Reynolds TC, Smith SD, Sklar J (1991) TAN-1, the human homolog of the Drosophila notch gene, is broken by chromosomal translocations in T lymphoblastic neoplasms. Cell 66: 649-661
3. Hori K, Sen A, Artavanis-Tsakonas S (2013) Notch signaling at a glance. J Cell Sci 126: 2135-2140
4. Ladi E, Nichols JT, Ge W, Miyamoto A, Yao C, Yang LT, Boulter J, Sun YE, Kintner C, Weinmaster (2005) The divergent DSL ligand Dll3 does not activate Notch signaling but cell autonomously attenuates signaling induced by other DSL ligands. J Cell Biol 170: 983-992
5. Singh N, Phillips RA, Iscove NN, Egan SE (2000) Expression of notch receptors, notch ligands, and fringe genes in hematopoiesis. Exp Hematol 28: 527-534
6. Brou C, Logeat F, Gupta N, Bessia C, LeBail O, Doedens JR, Cumano A, Roux P, Black RA, Israël A (2000) A novel proteolytic cleavage involved in Notch signaling: the role of the disintegrin-metalloprotease TACE. Mol Cell 5: 207-216
7. Bigas A, Espinosa L (2012) Hematopoietic stem cells: to be or Notch to be. Blood 119: 3226-3235
8. Artavanis-Tsakonas S, Rand MD, Lake RJ (1999) Notch signaling: cell fate control and signal integration in development. Science 284: 770-776
9. Tsunematsu R, Nakayama K, Oike Y, Nishiyama M, Ishida N, Hatakeyama S, Bessho Y, Kageyama R, Suda T, Nakayama KI (2004) Mouse Fbw7/Sel-10/Cdc4 is required for notch degradation during vascular development. J Biol Chem 279: 9417-9423
10. Martinez Arias A, Zecchini V, Brennan K (2002) CSL-independent Notch signalling: a checkpoint in cell fate decisions during development? Curr Opin Genet Dev 12: 524-533
11. Hurlbut GD, Kankel MW, Lake RJ, Artavanis-Tsakonas S (2007) Crossing paths with Notch in the hyper-network. Curr Opin Cell Biol 19: 166-175
12. Guruharsha KG, Kankel MW, Artavanis-Tsakonas S (2012) The Notch signalling system: recent insights into the complexity of a conserved pathway. Nat Rev Genet 13: 654-666
13. Guezguez B, Campbell CJ, Boyd AL, Karanu F, Casado FL, Di Cresce C, Collins TJ, Shapovalova Z, Xenocostas A, Bhatia M (2013) Regional localization within the bone marrow influences the functional capacity of human HSCs. Cell Stem Cell 13: 175-189
14. Lobry C, Ntziachristos P, Ndiaye-Lobry D, Oh P, Cimmino L, Zhu N, Araldi E, Hu W, Freund J, Abdel-Wahab O et al (2013) Notch pathway activation targets AML-initiating cell homeostasis and differentiation. J Exp Med 210: 301-319
15. Oh P, Lobry C, Gao J, Tikhonova A, Loizou E, Manent J, van Handel B, Ibrahim S, Greve J, Mikkola H et al (2013) In vivo mapping of notch pathway activity in normal and stress hematopoiesis. Cell Stem Cell 13: 190-204
16. Weng AP, Ferrando AA, Lee W, Morris J, Silverman LB, Sanchez-Irizarry C, Blacklow SC, Look AT, Aster JC (2004) Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science 306: 269-271.
17. Thompson BJ, Buonamici S, Sulis ML, Palomero T, Vilimas T, Basso G, Ferrando A, Aifantis I (2007) The SCFFBW7 ubiquitin ligase complex as a tumor suppressor in T cell leukemia. J Exp Med 204: 1825-1835
18. Ferrando AA, Neuberg DS, Staunton J, Loh ML, Huard C, Raimondi SC, Behm FG, Pui CH, Downing JR, Gilliland DG et al (2002) Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia. Cancer Cell 1: 75-87
19. Chiang MY, Xu L, Shestova O, Histen G, L'heureux S, Romany C, Childs ME, Gimotty PA, Aster JC, Pear WS (2008) Leukemia-associated NOTCH1 alleles are weak tumor initiators but accelerate K-ras-initiated leukemia. J Clin Invest 118: 3181-3194
20. Ashworth TD, Pear WS, Chiang MY, Blacklow SC, Mastio J, Xu L, Kelliher M, Kastner P, Chan S, Aster JC (2010) Deletion-based mechanisms of Notch1 activation in T-ALL: key roles for RAG recombinase and a conserved internal translational start site in Notch1. Blood 116: 5455-5464
21. Kong G, Du J, Liu Y, Meline B, Chang YI, Ranheim EA, Wang J, Zhang J (2013) Notch1 gene mutations target KRAS G12D-expressing CD8+ cells and contribute to their leukemogenic transformation. J Biol Chem 288: 18219-18227
22. Hallek M (2013) Chronic lymphocytic leukemia: 2013 update on diagnosis, risk stratification and treatment. Am J Hematol 88: 803-816
23. Rosati E, Sabatini R, Rampino G, Tabilio A, Di Ianni M, Fettucciari K, Bartoli A, Coaccioli S, Screpanti I, Marconi P (2009) Constitutively activated Notch signaling is involved in survival and apoptosis resistance of B-CLL cells. Blood 113: 856-865
24. Puente XS, Pinyol M, Quesada V, Conde L, Ordóñez GR, Villamor N, Escaramis G, Jares P, Beà S, González-Díaz M et al (2011) Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature 475: 101-105
25. Olsauskas-Kuprys R, Zlobin A, Osipo C (2013) Gamma secretase inhibitors of Notch signaling. Onco Targets Ther 6: 943-955
26. Larrivee B, Prahst C, Gordon E, del Toro R, Mathivet T, Duarte A, Simons M, Eichmann A (2012) ALK1 signaling inhibits angiogenesis by cooperating with the Notch pathway. Dev Cell 22: 489-500
27. Zweidler-McKay PA, He Y, Xu L, Rodriguez CG, Karnell FG, Carpenter AC, Aster JC, Allman D, Pear WS (2005) Notch signaling is a potent inducer of growth arrest and apoptosis in a wide range of B-cell malignancies. Blood 106: 3898-3906
28. Alghisi E, Distel M, Malagola M, Anelli V, Santoriello C, Herwig L, Krudewig A, Henkel CV, Russo D, Mione MC (2013) Targeting oncogene expression to endothelial cells induces proliferation of the myelo-erythroid lineage by repressing the Notch pathway. Leukemia 27: 2229-2241
29. Klinakis A, Lobry C, Abdel-Wahab O, Oh P, Haeno H, Buonamici S, van De Walle I, Cathelin S, Trimarchi T, Araldi E et al (2011) A novel tumour-suppressor function for the Notch pathway in myeloid leukaemia. Nature 473: 230-233
30. Hideshima T, Anderson KC (2002) Molecular mechanisms of novel therapeutic approaches for multiple myeloma. Nat Rev Cancer 2: 927-937
31. Houde C, Li Y, Song L, Barton K, Zhang Q, Godwin J, Nand S, Toor A, Alkan S, Smadja NV, Avet-Loiseau H et al (2004) Overexpression of the NOTCH ligand JAG2 in malignant plasma cells from multiple myeloma patients and cell lines. Blood 104: 3697-3704
32. Mirandola L, Apicella L, Colombo M, Yu Y, Berta DG, Platonova N, Lazzari E, Lancellotti M, Bulfamante G, Cobos E et al (2013) Anti-Notch treatment prevents multiple myeloma cells localization to the bone marrow via the chemokine system CXCR4/SDF-1. Leukemia 27: 1558-1566
33. Nwabo Kamdje AH, Krampera M (2011) Notch signaling in acute lymphoblastic leukemia: any role for stromal microenvironment? Blood 118: 6506-6514
34. Nwabo Kamdje AH, Bassi G, Pacelli L, Malpeli G, Amati E, Nichele I, Pizzolo G, Krampera M (2012) Role of stromal cell-mediated Notch signaling in CLL resistance to chemotherapy. Blood Cancer J 2: e73
35. Winter SS, Sweatman JJ, Lawrence MB, Rhoades TH, Hart AL, Larson RS (2001) Enhanced T-lineage acute lymphoblastic leukaemia cell survival on bone marrow stroma requires involvement of LFA-1 and ICAM-1. Br J Haematol 115: 862-871
36. Zhang J, Ye J, Ma D, Liu N, Wu H, Yu S, Sun X, Tse W, Ji C (2013) Cross - talk between leukemic and endothelial cells promotes angiogenesis by VEGF activation of the Notch/Dll4 pathway. Carcinogenesis 34: 667-677
37. Kode A, Manavalan JS, Mosialou I, Bhagat G, Rathinam CV, Luo N, Khiabanian H, Lee A, Murty VV, Friedman R et al (2014) Leukaemogenesis induced by an activating beta-catenin mutation in osteoblasts. Nature 506: 240-244
38. Wang L, Zhang H, Rodriguez S, Cao L, Parish J, Mumaw C, Zollman A, Kamoka MM, Mu J, Chen DZ et al (2014) Notch-dependent repression of miR-155 in the bone marrow niche regulates hematopoiesis in an NF-kappaB-dependent manner. Cell Stem Cell 15: 51-65
39. Miele L, Golde T, Osborne B (2006) Notch signaling in cancer. Curr Mol Med 6: 905-918
40. Beets K, Huylebroeck D, Moya IM, Umans L, Zwijsen A (2013) Robustness in angiogenesis: notch and BMP shaping waves. Trends Genet 29: 140-149
41. Fan X, Khaki L, Zhu TS, Soules ME, Talsma CE, Gul N, Koh C, Zhang J, Li YM, Maciaczyk J et al (2010) NOTCH pathway blockade depletes CD133-positive glioblastoma cells and inhibits growth of tumor neurospheres and xenografts. Stem Cells 28: 5-16
42. Lee KS, Wu Z, Song Y, Mitra SS, Feroze AH, Cheshier SH, Lu B (2013) Roles of PINK1, mTORC 2, and mitochondria in preserving brain tumor-forming stem cells in a noncanonical Notch signaling pathway. Genes Dev 27: 2642-2647
43. Wang Y, Liu Y, Malek SN, Zheng P (2011) Targeting HIF1alpha eliminates cancer stem cells in hematological malignancies. Cell Stem Cell 8: 399-411
44. van Es JH, van Gijn ME, Riccio O, van den Born M, Vooijs M, Begthel H, Cozijnsen M, Robine S, Winton DJ, Radtke F et al (2005) Notch/gamma-secretase inhibition turns proliferative cells in intestinal crypts and adenomas into goblet cells. Nature 435: 959-963
45. Palomero T, Sulis ML, Cortina M, Real PJ, Barnes K, Ciofani M, Caparros E, Buteau J, Brown K, Perkins SL et al (2007) Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemia. Nat Med 13: 1203-1210
46. Real PJ, Tosello V, Palomero T, Castillo M, Hernando E, de Stanchina E, Sulis ML, Barnes K, Sawai C, Homminga I et al (2009) Gamma-secretase inhibitors reverse glucocorticoid resistance in T cell acute lymphoblastic leukemia. Nat Med 15: 50-58
47. Rosati E, Sabatini R, De Falco F, Del Papa B, Falzetti F, Di Ianni M, Cavalli L, Fettucciari K, Bartoli A, Screpanti I et al (2013) gamma-Secretase inhibitor I induces apoptosis in chronic lymphocytic leukemia cells by proteasome inhibition, endoplasmic reticulum stress increase and notch down-regulation. Int J Cancer 132: 1940-1953
48. Ramakrishnan V, Ansell S, Haug J, Grote D, Kimlinger T, Stenson M, Timm M, Wellik L, Halling T, Rajkumar SV et al (2012) MRK003, a gamma-secretase inhibitor exhibits promising in vitro pre-clinical activity in multiple myeloma and non-Hodgkin's lymphoma. Leukemia 26: 340-348
49. Floyd DH, Kefas B, Seleverstov O, Mykhaylyk O, Dominguez C, Comeau L, Plank C, Purow B (2012) Alpha-secretase inhibition reduces human glioblastoma stem cell growth in vitro and in vivo by inhibiting Notch. Neuro Oncol 14: 1215-1226
50. Wu Y, Cain-Hom C, Choy L, Hagenbeek TJ, de Leon GP, Chen Y, Finkle D, Venook R, Wu X, Ridgway J et al (2010) Therapeutic antibody targeting of individual Notch receptors. Nature 464: 1052-1057
51. Aste-Amézaga M, Zhang N, Lineberger JE, Arnold BA, Toner TJ, Gu M, Huang L, Vitelli S, Vo KT, Haytko P et al (2010) Characterization of Notch1 antibodies that inhibit signaling of both normal and mutated Notch1 receptors. PLoS ONE 5: e9094
52. Agnusdei V, Minuzzo S, Frasson C, Grassi A, Axelrod F, Satyal S, Gurney A, Hoey T, Seganfreddo E, Basso G et al (2014) Therapeutic antibody targeting of Notch1 in T-acute lymphoblastic leukemia xenografts. Leukemia 28: 278-288
53. Pastò A, Serafin V, Pilotto G, Lago C, Bellio C, Trusolino L, Bertotti A, Hoey T, Plateroti M, Esposito G et al (2014) NOTCH3 signaling regulates MUSASHI-1 expression in metastatic colorectal cancer cells. Cancer Res 74: 2106-2118
54. Li K, Li Y, Wu W, Gordon WR, Chang DW, Lu M, Scoggin S, Fu T, Vien L, Histen G et al (2008) Modulation of Notch signaling by antibodies specific for the extracellular negative regulatory region of NOTCH3. J Biol Chem 283: 8046-8054
55. Fischer M, Yen WC, Kapoun AM, Wang M, O'Young G, Lewicki J, Gurney A, Hoey T (2011) Anti-DLL4 inhibits growth and reduces tumor-initiating cell frequency in colorectal tumors with oncogenic KRAS mutations. Cancer Res 71: 1520-1525
56. Liu SK, Bham SA, Fokas E, Beech J, Im J, Cho S, Harris AL, Muschel RJ (2011) Delta-like ligand 4-notch blockade and tumor radiation response. J Natl Cancer Inst 103: 1778-1798
57. Yan XQ, Sarmiento U, Sun Y, Huang G, Guo J, Juan T, Van G, Qi MY, Scully S, Senaldi G et al (2001) A novel Notch ligand, Dll4, induces T-cell leukemia/lymphoma when overexpressed in mice by retroviral-mediated gene transfer. Blood 98: 3793-3799
58. Samore WR, Gondi CS (2014) Brief overview of selected approaches in targeting pancreatic adenocarcinoma. Expert Opin Investig Drugs 23: 793-807
59. Moellering RE, Cornejo M, Davis TN, Del Bianco C, Aster JC, Blacklow SC, Kung AL, Gilliland DG, Verdine GL, Bradner JE (2009) Direct inhibition of the NOTCH transcription factor complex. Nature 462: 182-188
60. Sulis ML, Saftig P, Ferrando AA (2011) Redundancy and specificity of the metalloprotease system mediating oncogenic NOTCH1 activation in T-ALL. Leukemia 25: 1564-1569
61. Koyama D, Kikuchi J, Hiraoka N, Wada T, Kurosawa H, Chiba S, Furukawa Y (2014) Proteasome inhibitors exert cytotoxicity and increase chemosensitivity via transcriptional repression of Notch1 in T-cell acute lymphoblastic leukemia. Leukemia 28: 1216-1226
62. Matsuoka S, Oike Y, Onoyama I, Iwama A, Arai F, Takubo K, Mashimo Y, Oguro H, Nitta E, Ito K et al (2008) Fbxw7 acts as a critical fail-safe against premature loss of hematopoietic stem cells and development of T-ALL. Genes Dev 22: 986-991
63. O'Neil J, Grim J, Strack P, Rao S, Tibbitts D, Winter C, Hardwick J, Welcker M, Meijerink JP, Pieters R et al (2007) FBW7 mutations in leukemic cells mediate NOTCH pathway activation and resistance to gamma-secretase inhibitors. J Exp Med 204: 1813-1824
64. Roti G, Carlton A, Ross KN, Markstein M, Pajcini K, Su AH, Perrimon N, Pear WS, Kung AL, Blacklow SC et al (2013) Complementary genomic screens identify SERCA as a therapeutic target in NOTCH 1 mutated cancer. Cancer Cell 23: 390-405
65. Karanu FN, Murdoch B, Miyabayashi T, Ohno M, Koremoto M, Gallacher L, Wu D, Itoh A, Sakano S, Bhatia M (2001) Human homologues of Delta-1 and Delta-4 function as mitogenic regulators of primitive human hematopoietic cells. Blood 97: 1960-1967
66. Suzuki T, Yokoyama Y, Kumano K, Takanashi M, Kozuma S, Takato T, Nakahata T, Nishikawa M, Sakano S, Kurokawa M et al (2006) Highly efficient ex vivo expansion of human hematopoietic stem cells using Delta1-Fc chimeric protein. Stem Cells 24: 2456-2465
67. Delaney C, Varnum-Finney B, Aoyama K, Brashem-Stein C, Bernstein ID (2005) Dose-dependent effects of the Notch ligand Delta 1 on ex vivo differentiation and in vivo marrow repopulating ability of cord blood cells. Blood 106: 2693-2699
68. Lauret E, Catelain C, Titeux M, Poirault S, Dando JS, Dorsch M, Villeval JL, Groseil A, Vainchenker W, Sainteny F et al (2004) Membrane-bound delta-4 notch ligand reduces the proliferative activity of primitive human hematopoietic CD34+CD38low cells while maintaining their LTC-IC potential. Leukemia 18: 788-797
69. Vercauteren SM, Sutherland HJ (2004) Constitutively active Notch4 promotes early human hematopoietic progenitor cell maintenance while inhibiting differentiation and causes lymphoid abnormalities in vivo. Blood 104: 2315-2322
70. Yamamura K, Ohishi K, Katayama N, Kato K, Shibasaki T, Sugimoto Y, Miyata E, Shiku H, Masuya M, Nishioka J et al (2007) Notch ligand Delta -1 differentially modulates the effects of gp130 activation on interleukin-6 receptor alpha-positive and-negative human hematopoietic progenitors. Cancer Sci 98: 1597-1603
71. Neves H, Weerkamp F, Gomes AC, Naber BA, Gameiro P, Becker JD, Lúcio P, Clode N, van Dongen JJ, Staal FJ et al (2006) Effects of Delta1 and Jagged1 on early human hematopoiesis: correlation with expression of notch signaling-related genes in CD34+ cells. Stem Cells 24: 1328-1337
72. Sugimoto A, Yamamoto M, Suzuki M, Inoue T, Nakamura S, Motoda R, Yamasaki F, Orita K (2006) Delta-4 Notch ligand promotes erythroid differentiation of human umbilical cord blood CD34+ cells. Exp Hematol 34: 424-432
73. Lefort N, Benne C, Lelievre JD, Dorival C, Balbo M, Sakano S, Coulombel L, Levy Y (2006) Short exposure to Notch ligand Delta-4 is sufficient to induce T-cell differentiation program and to increase the T cell potential of primary human CD34+ cells. Exp Hematol 34: 1720-1729
74. Tanigaki K, Han H, Yamamoto N, Tashiro K, Ikegawa M, Kuroda K, Suzuki A, Nakano T, Honjo T (2002) Notch-RBP-J signaling is involved in cell fate determination of marginal zone B cells. Nat Immunol 3: 443-450
75. Tanigaki K, Tsuji M, Yamamoto N, Han H, Tsukada J, Inoue H, Kubo M, Honjo T (2004) Regulation of alphabeta/gammadelta T cell lineage commitment and peripheral T cell responses by Notch/RBP-J signaling. Immunity 20: 611-622
76. Maillard I, Tu L, Sambandam A, Yashiro-Ohtani Y, Millholland J, Keeshan K, Shestova O, Xu L, Bhandoola A, Pear WS (2006) The requirement for Notch signaling at the beta-selection checkpoint in vivo is absolute and independent of the pre-T cell receptor. J Exp Med 203: 2239-2245
77. Maillard I, Weng AP, Carpenter AC, Rodriguez CG, Sai H, Xu L, Allman D, Aster JC, Pear WS (2004) Mastermind critically regulates Notch-mediated lymphoid cell fate decisions. Blood 104: 1696-1702
78. Hori K, Cholewa-Waclaw J, Nakada Y, Glasgow SM, Masui T, Henke RM, Wildner H, Martarelli B, Beres TM, Epstein JA et al (2008) A nonclassical bHLH Rbpj transcription factor complex is required for specification of GABAergic neurons independent of Notch signaling. Genes Dev 22: 166-178
79. Carlesso N, Aster JC, Sklar J, Scadden DT (1999) Notch 1-induced delay of human hematopoietic progenitor cell differentiation is associated with altered cell cycle kinetics. Blood 93: 838-848
80. Chadwick N, Nostro MC, Baron M, Mottram R, Brady G, Buckle AM (2007) Notch signaling induces apoptosis in primary human CD34+ hematopoietic progenitor cells. Stem Cells 25: 203-210
81. Calvi LM, Adams GB, Weibrecht KW, Weber JM, Olson DP, Knight MC, Martin RP, Schipani E, Divieti P, Bringhurst FR et al (2003) Osteoblastic cells regulate the haematopoietic stem cell niche. Nature 425: 841-846
82. Maeda T, Merghoub T, Hobbs RM, Dong L, Maeda M, Zakrzewski J, van den Brink MR, Zelent A, Shigematsu H, Akashi K et al (2007) Regulation of B versus T lymphoid lineage fate decision by the proto-oncogene LRF. Science 316: 860-866
83. Benveniste P, Serra P, Dervovic D, Herer E, Knowles G, Mohtashami M, Zuniga-Pflucker JC (2014) Notch signals are required for in vitro but not in vivo maintenance of human hematopoietic stem cells and delay the appearance of multipotent progenitors. Blood 123: 1167-1177
84. Delaney C, Heimfeld S, Brashem-Stein C, Voorhies H, Manger RL, Bernstein ID (2010) Notch-mediated expansion of human cord blood progenitor cells capable of rapid myeloid reconstitution. Nat Med 16: 232-236
85. Hisa T, Spence SE, Rachel RA, Fujita M, Nakamura T, Ward JM, Devor-Henneman DE, Saiki Y, Kutsuna H, Tessarollo L et al (2004) Hematopoietic, angiogenic and eye defects in Meis1 mutant animals. EMBO J 23: 450-459
86. Suh HC, Gooya J, Renn K, Friedman AD, Johnson PF, Keller JR (2006) C/EBPalpha determines hematopoietic cell fate in multipotential progenitor cells by inhibiting erythroid differentiation and inducing myeloid differentiation. Blood 107: 4308-4316
87. Karanu FN, Murdoch B, Gallacher L, Wu DM, Koremoto M, Sakano S, Bhatia M (2000) The notch ligand jagged-1 represents a novel growth factor of human hematopoietic stem cells. J Exp Med 192: 1365-1372
88. Schroeder T, Kohlhof H, Rieber N, Just U (2003) Notch signaling induces multilineage myeloid differentiation and up-regulates PU.1 expression. J Immunol 170: 5538-5548
89. Kim YW, Koo BK, Jeong HW, Yoon MJ, Song R, Shin J, Jeong DC, Kim SH, Kong YY (2008) Defective Notch activation in microenvironment leads to myeloproliferative disease. Blood 112: 4628-4638
90. Hirschi KK (2012) Hemogenic endothelium during development and beyond. Blood 119: 4823-4827
91. Yu X, Zou J, Ye Z, Hammond H, Chen G, Tokunaga A, Mali P, Li YM, Civin C, Gaiano N et al (2008) Notch signaling activation in human embryonic stem cells is required for embryonic, but not trophoblastic, lineage commitment. Cell Stem Cell 2: 461-471
92. Cheng X, Huber TL, Chen VC, Gadue P, Keller GM (2008) Numb mediates the interaction between Wnt and Notch to modulate primitive erythropoietic specification from the hemangioblast. Development 135: 3447-3458
93. Chiba S (2006) Notch signaling in stem cell systems. Stem Cells 24: 2437-2447
94. Kumano K, Chiba S, Kunisato A, Sata M, Saito T, Nakagami-Yamaguchi E, Yamaguchi T, Masuda S, Shimizu K, Takahashi T et al (2003) Notch1 but not Notch2 is essential for generating hematopoietic stem cells from endothelial cells. Immunity 18: 699-711
95. Marks-Bluth J, Pimanda JE (2012) Cell signalling pathways that mediate haematopoietic stem cell specification. Int J Biochem Cell Biol 44: 2175-2184
96. Nostro MC, Cheng X, Keller GM, Gadue P (2008) Wnt, activin, and BMP signaling regulate distinct stages in the developmental pathway from embryonic stem cells to blood. Cell Stem Cell 2: 60-71
97. Lee JB, Werbowetski-Ogilvie TE, Lee JH, McIntyre BA, Schnerch A, Hong SH, Park IH, Daley GQ, Bernstein ID, Bhatia M (2013) Notch-HES1 signaling axis controls hemato-endothelial fate decisions of human embryonic and induced pluripotent stem cells. Blood 122: 1162-1173
98. Amabile G, Welner RS, Nombela-Arrieta C, D'Alise AM, Di Ruscio A, Ebralidze AK, Kraytsberg Y, Ye M, Kocher O, Neuberg DS et al (2013) In vivo generation of transplantable human hematopoietic cells from induced pluripotent stem cells. Blood 121: 1255-1264
99. Bhatia M, Bonnet D, Murdoch B, Gan OI, Dick JE (1998) A newly discovered class of human hematopoietic cells with SCID-repopulating activity. Nat Med 4: 1038-1045
100. Galic Z, Kitchen SG, Kacena A, Subramanian A, Burke B, Cortado R, Zack JA (2006) T lineage differentiation from human embryonic stem cells. Proc Natl Acad Sci USA 103: 11742-11747
101. Kennedy M, Awong G, Sturgeon CM, Ditadi A, LaMotte-Mohs R, Zuniga-Pflucker JC, Keller G (2012) T lymphocyte potential marks the emergence of definitive hematopoietic progenitors in human pluripotent stem cell differentiation cultures. Cell Rep 2: 1722-1735
102. Themeli M, Kloss CC, Ciriello G, Fedorov VD, Perna F, Gonen M, Sadelain M (2013) Generation of tumor-targeted human T lymphocytes from induced pluripotent stem cells for cancer therapy. Nat Biotechnol 31: 928-933
103. Timmermans F, Velghe I, Vanwalleghem L, De Smedt M, Van Coppernolle S, Taghon T, Moore HD, Leclercq G, Langerak AW, Kerre T et al (2009) Generation of T cells from human embryonic stem cell-derived hematopoietic zones. J Immunol 182: 6879-6888
104. Vizcardo R, Masuda K, Yamada D, Ikawa T, Shimizu K, Fujii S, Koseki H, Kawamoto H (2013) Regeneration of human tumor antigen-specific T cells from iPSCs derived from mature CD8(+) T cells. Cell Stem Cell 12: 31-36